5 amino 1mq dosing human 5-Amino-1MQ | ≥99% Pure 5-AMINO-1MQ Peptide | Elase
Description
Methods Enzymol

This Phase 2b failure effectively terminated clinical development for obesity

A single 50 mg vial provides 1020 days of research material at these doses

However, seeking medical guidance is crucial to ensure safe and effective use

Early human trials in people with obesity found that daily AOD9604 was well tolerated and had a safety profile similar to placebo, with no major effects on glucose metabolism or IGF1, though weightloss results were modest and inconsistent
